Ribosomal L22-like1 (RPL22L1) Promotes Ovarian Cancer Metastasis by Inducing Epithelial-to-Mesenchymal Transition

Wu, Nan; Jia, Wei Hua; Wang, Yuhui; Yan, Jinyan; Qin, Ying; Tong, Dandan; Pang, Bo; Sun, Donglin; Sun, Haiming; Ye, Yu; Sun, Wenjing; Meng, Xin; Zhang, Chunyu; Bai, Jing; Chen, Feng; Geng, Jingshu; Lee, Ki-Young; Fu, Songbin; Jin, Yan

doi:10.1371/journal.pone.0143659

Cited by 26 publications

(22 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The fifth key gene was RPL22L1, which was identified as a trace component of ribosome ( 31 , 32 ). Wu et al reported that RPL22L1 could promote ovarian cancer metastasis by inducing epithelial-to-mesenchymal transition ( 33 ). Moreover, recent study also demonstrated that RPL22L1 could play vital and definite roles in hematopoietic development ( 34 ).…”

Section: Discussionmentioning

confidence: 99%

Identification of the key genes and pathways in prostate cancer

et al. 2018

View full text Add to dashboard Cite

Prostate cancer (PCa) is one of the most common malignancies in men globally. The aim of the present study was to identify the key genes and pathways involved in the occurrence of PCa. Gene expression profile (GSE55945) was downloaded from Gene Expression Omnibus, and the differentially expressed genes (DEGs) were identified. Subsequently, Gene ontology analysis, KEGG pathway analysis and protein-protein interaction (PPI) analysis of DEGs were performed. Finally, the identified key genes were confirmed by immunohistochemistry. The GO analysis results showed that the DEGs were mainly participated in cell cycle, cell division, cell development and cell junction. The KEGG pathway analysis showed that the DEGs were mainly enriched in proteoglycans in cancer, endocytosis, focal adhesion and hippo signaling pathway. The PPI analysis results showed that RPS21, FOXO1, BIRC5, POLR2H, RPL22L1 and NPM1 were the key genes involved in the occurrence of PCa, and the Module analysis indicated that the occurrence of PCa was associated with cell cycle, oocyte meiosis and ribosome biogenesis. IHC result showed that the expression of RPS21, BIRC5, POLR2H, RPL22L1 and NPM1 were significantly upregulated in PCa, while the expression of FOXO1 was significantly downregulated in PCa, matching with the bioinformatics analysis. Taken together, several key genes and pathways were identified involved in PCa, which might provide the potential biomarker for prognosis, diagnosis and drug targets.

show abstract

Section: Discussionmentioning

confidence: 99%

Identification of the key genes and pathways in prostate cancer

et al. 2018

View full text Add to dashboard Cite

show abstract

“…RPL22L1 still ranks first by p-value, after MYCN mRNA, even with all mRNAs included (p = 4.35 × 10 −74 , plot not shown). RPL22L1 has not been investigated in neuroblastoma, however it is over-expressed in metastasising and invasive ovarian tumour tissues, corresponding with the increased DNA copy number [22]. Although originally located on the 3q26.2 locus, the amplified RPL22L1 gene is co-located with amplified MYCN DNA in double minute chromosomes in the UACC-1598 ovarian cancer cell line.…”

Section: Ribosomal Proteins: Rpl22l1 Rpl39 Rpl18a Rpl36 Rpl35 Rps3mentioning

confidence: 99%

Identification of RNA-Binding Proteins as Targetable Putative Oncogenes in Neuroblastoma

Bell

Hagemann

Holien

et al. 2020

IJMS

View full text Add to dashboard Cite

Neuroblastoma is a common childhood cancer with almost a third of those affected still dying, thus new therapeutic strategies need to be explored. Current experimental therapies focus mostly on inhibiting oncogenic transcription factor signalling. Although LIN28B, DICER and other RNA-binding proteins (RBPs) have reported roles in neuroblastoma development and patient outcome, the role of RBPs in neuroblastoma is relatively unstudied. In order to elucidate novel RBPs involved in MYCN-amplified and other high-risk neuroblastoma subtypes, we performed differential mRNA expression analysis of RBPs in a large primary tumour cohort (n = 498). Additionally, we found via Kaplan–Meier scanning analysis that 685 of the 1483 tested RBPs have prognostic value in neuroblastoma. For the top putative oncogenic candidates, we analysed their expression in neuroblastoma cell lines, as well as summarised their characteristics and existence of chemical inhibitors. Moreover, to help explain their association with neuroblastoma subtypes, we reviewed candidate RBPs’ potential as biomarkers, and their mechanistic roles in neuronal and cancer contexts. We found several highly significant RBPs including RPL22L1, RNASEH2A, PTRH2, MRPL11 and AFF2, which remain uncharacterised in neuroblastoma. Although not all RBPs appear suitable for drug design, or carry prognostic significance, we show that several RBPs have strong rationale for inhibition and mechanistic studies, representing an alternative, but nonetheless promising therapeutic strategy in neuroblastoma treatment.

show abstract

“…Double minute chromosomes are extrachromosomal cytogenetic structures and commonly found to carry oncogenes in various cancers, including epidermal growth factor receptor in gliomas, C‐MYC in CRC, and EIF5A2 or RPL22L1 in ovarian cancer. In the report presented here, we identified a novel CRC metastasis‐related gene, namely NUBPL , that was also amplified on DMs.…”

Section: Discussionmentioning

confidence: 99%

NUBPL, a novel metastasis‐related gene, promotes colorectal carcinoma cell motility by inducing epithelial–mesenchymal transition

Wang

Sun

et al. 2017

Cancer Science

Self Cite

View full text Add to dashboard Cite

Nucleotide binding protein‐like, NUBPL, is an assembly factor for human mitochondrial complex I, which is the biggest member of the mitochondrial respiratory chain. However, the relationship between NUBPL and carcinoma progression remains unknown. In this study, NUBPL was characterized for its role in colorectal cancer (CRC) and the underlying molecular mechanisms. Data (n = 197) from the Oncomine database revealed that mRNA levels of NUBPL were remarkably overexpressed in CRC tissues compared with normal tissues. In addition, immunohistochemical analysis of 75 pairs of CRC and non‐tumor tissues showed that the expression level of NUBPL was significantly higher in CRC tissues, and its expression level was positively associated with lymph node metastasis (P = 0.028) and advanced staging (P = 0.030). Expression of NUBPL in metastatic lymph nodes of CRC patients was also detected by immunohistochemical staining and high expression levels of NUBPL were observed. Overexpression of NUBPL significantly promoted the migration and invasion ability of CRC cell lines SW480 and SW620, whereas knockdown of NUBPL lead to an opposite effect. Our further study found that NUBPL could induce epithelial–mesenchymal transition (EMT), characterized by downregulation of epithelial markers (E‐cadherin) and upregulation of mesenchymal markers (N‐cadherin and vimentin). Moreover, NUBPL was able to activate ERK, which is believed to promote EMT and tumor metastasis. Inhibition of ERK suppressed the NUBPL‐induced changes in EMT and cell motility. These data showed that NUBPL plays a vital role in CRC migration and invasion by inducing EMT and activating ERK. It might be a novel therapeutic target for CRC.

show abstract

Ribosomal L22-like1 (RPL22L1) Promotes Ovarian Cancer Metastasis by Inducing Epithelial-to-Mesenchymal Transition

Cited by 26 publications

References 39 publications

Identification of the key genes and pathways in prostate cancer

Identification of the key genes and pathways in prostate cancer

Identification of RNA-Binding Proteins as Targetable Putative Oncogenes in Neuroblastoma

NUBPL, a novel metastasis‐related gene, promotes colorectal carcinoma cell motility by inducing epithelial–mesenchymal transition

Contact Info

Product

Resources

About